Cancer combo trial halted before full results
NCT ID NCT04284488
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors including colorectal, nasopharyngeal, and lung cancers. The goal was to find a safe dose and see if the combination could control the disease. However, the study was terminated early, so we have limited information on how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APG-1387 and toripalimab (a type of immunotherapy)
What this could lead to
If it had succeeded, this combination might have offered a new treatment option for certain advanced cancers that are hard to treat.
What could go wrong
The trial was terminated early, so results are limited. The study was small and early-stage, meaning even if it worked, it would need much more testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Foshan First People's Hospital
Foshan, Guangdong, China
-
Sun-Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The Affiliated Hospital OF Guangxi Medical University
Nanning, Guangxi, 530021, China